Correlation between Peak Absolute Lymphocyte Count Post Brexucabtagene Autoleucel Infusion and Outcomes in Mantle Cell Lymphoma

被引：0
|
作者：
Atallah-Yunes, Albert [1 ]
Rees, Matthew James [1 ]
Munoz, Javier [2 ]
Paludo, Jonas [1 ]
Moustafa, Muhamad Alhaj [3 ]
Khurana, Arushi [1 ]
Bisneto, Jose C. Villasboas [4 ]
Rosenthal, Allison C. [5 ]
Castro, Januario E. [6 ]
Iqbal, Madiha [7 ]
Kharfan-Dabaja, Mohamed A. [8 ]
Bennani, N. Nora [1 ]
Hampel, Paul J. [1 ]
Durani, Urshila [1 ]
Johnston, Patrick B. [1 ]
Corraes, Andre De Menezes Silva [1 ]
Porrata, Luis [1 ]
Ansell, Stephen M. [1 ]
Lin, Yi [1 ]
Wang, Yucai [1 ]
机构：
[1] Mayo Clin, Div Hematol, Rochester, MN USA
[2] Mayo Clin, Phoenix, AZ USA
[3] Mayo Clin, Div Hematol, Jacksonville, FL USA
[4] Mayo Clin, Rochester, MN USA
[5] Mayo Clin, Div Hematol Oncol, Phoenix, AZ USA
[6] Mayo Clin, Div Hematol & Med Oncol, Phoenix, AZ USA
[7] Mayo Clin, Div Hematol & Med Oncol, Jacksonville, FL USA
[8] Mayo Clin, Dept Hematol Oncol, Jacksonville, FL USA
来源：
BLOOD | 2024年 / 144卷
关键词：
D O I：
10.1182/blood-2024-200408
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1651 / 1652
页数：2
相关论文
共 50 条
  • [1] Outcomes with bendamustine lymphodepletion prior to brexucabtagene autoleucel for mantle cell lymphoma
    Chong, Elise A.
    Gerson, James N.
    Nasta, Sunita Dwivedy
    Landsburg, Daniel J.
    Barta, Stefan K.
    Svoboda, Jakub
    Weber, Elizabeth
    Chong, Emeline R.
    Schuster, Stephen J.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [2] Bendamustine as Lymphodepletion for Brexucabtagene Autoleucel Therapy of Mantle Cell Lymphoma
    Chong, Elise A.
    Chong, Emeline R.
    Therwhanger, Dylan
    Nasta, Sunita D.
    Landsburg, Daniel J.
    Barta, Stefan K.
    Svoboda, Jakub
    Gerson, James N.
    Ghilardi, Guido
    Paruzzo, Luca
    Fraietta, Joseph A.
    Weber, Elizabeth
    Stefano, Natalie
    Porter, David L.
    V. Frey, Noelle
    Garfall, Alfred L.
    Ruella, Marco
    Schuster, Stephen J.
    TRANSPLANTATION AND CELLULAR THERAPY, 2024, 30 (07): : 726e1 - 726e8
  • [3] Outcomes and management of patients with mantle cell lymphoma after progression on brexucabtagene autoleucel therapy
    Jain, Preetesh
    Nastoupil, Loretta
    Westin, Jason
    Lee, Hun Ju
    Navsaria, Lucy
    Steiner, Raphael E.
    Ahmed, Sairah
    Moghrabi, Omar
    Oriabure, Onyeka
    Chen, Wendy
    Badillo, Maria
    Flowers, Christopher R.
    Wang, Michael L.
    BRITISH JOURNAL OF HAEMATOLOGY, 2021, 192 (02) : E38 - E42
  • [4] Brexucabtagene autoleucel for the treatment of relapsed/refractory mantle cell lymphoma
    Mian, Agrima
    Hill, Brian T.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2021, 21 (04) : 435 - 441
  • [5] Analysis of Outcomes and Predictors of Response in Patients with Relapsed Mantle Cell Lymphoma Treated with Brexucabtagene Autoleucel
    Romancik, Jason T.
    Goyal, Subir
    Gerson, James N.
    Ballard, Hatcher J.
    Sawalha, Yazeed
    Bond, David A.
    Rogalski, Michael Joseph
    Greenwell, Irl Brian
    van Besien, Koen
    Yamshon, Samuel
    Karmali, Reem
    Nizamuddin, Imran
    Torka, Pallawi
    Chow, Victor A.
    Shadman, Mazyar
    Ghosh, Nilanjan
    Moyo, Tamara K.
    Fenske, Timothy S.
    Rezazadeh, Alexandra
    Grover, Natalie S.
    Maddocks, Kami J.
    Jacobson, Caron
    Cohen, Jonathon B.
    BLOOD, 2021, 138
  • [6] Brexucabtagene Autoleucel for Relapsed/Refractory Mantle Cell Lymphoma: Real-World Outcomes in the United Kingdom
    O'Reilly, Maeve A.
    Sanderson, Robin
    Wilson, William
    Burns, David
    Besley, Caroline
    Creasey, Thomas
    Uttenthal, Ben
    Elliot, Johnathon
    Roddie, Claire
    Kuhnl, Andrea
    Paneesha, Shankara
    Seymour, Frances
    Iyengar, Sunil
    Rubio, Lourdes
    Wilson, Matthew
    Boyle, Stephen
    Cheok, Kathleen Pl
    Collins, Graham P.
    Johnson, Rod
    McMillan, Andrew K.
    BLOOD, 2022, 140 : 7519 - 7521
  • [7] Cost-Effectiveness of brexucabtagene autoleucel for relapsed/refractory mantle cell lymphoma
    Marchetti, M.
    Visco, C.
    LEUKEMIA & LYMPHOMA, 2023, 64 (08) : 1442 - 1450
  • [8] Repeated Infusions of Brexucabtagene-autoleucel in Relapsed/Refractory Mantle Cell Lymphoma
    Aydilek, Enver
    Klein-Scory, Susanne
    Thomson, Julia
    Nilius-Eliliwi, Verena
    Vangala, Deepak
    Schroers, Roland
    Wulf, Gerald
    Mika, Thomas
    HEMASPHERE, 2023, 7 (09):
  • [9] Bridging Radiotherapy prior to Brexucabtagene Autoleucel for Relapsed/Refractory Mantle Cell Lymphoma
    Fetooh, A.
    Lionel, A.
    Fang, P.
    Nze, C. C.
    Ahmed, S.
    Westin, J.
    Flowers, C.
    Pinnix, C. C.
    Dabaja, B.
    Gunther, J. R.
    Neelapu, S. S.
    Wang, M. L.
    Jain, P.
    Wu, S. Y.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2024, 120 (02): : E622 - E623
  • [10] Bridging Radiotherapy prior to Brexucabtagene Autoleucel CAR T-Cell Therapy in Mantle Cell Lymphoma
    Figura, N.
    Sim, A.
    Dahiya, S.
    Lutfi, F.
    Rapoport, A.
    Mohindra, P.
    Dohm, A.
    Chavez, J.
    Shah, B.
    Khimani, F.
    Lazaryan, A.
    Davila, M.
    Bachmeier, C.
    Nishihori, T.
    Liu, H.
    Kim, S.
    Locke, F.
    Jain, M.
    Robinson, T.
    RADIOTHERAPY AND ONCOLOGY, 2021, 161 : S894 - S895
12345